Hans-Peter Gerber, Chief Scientific Officer of Sutro Biopharma, Inc., filed a Form 4 on September 22, 2026, disclosing transactions in the company's common stock dated September 18, 2026, related to the vesting of restricted stock units and associated tax withholding.

Key Highlights

  • RSU Vesting: 3,750 restricted stock units vested on September 18, 2026, acquired at $0 per share under transaction code M.
  • Shares Withheld for Taxes: 1,345 shares of common stock were withheld by the issuer at $15.34 per share to satisfy income tax withholding obligations in connection with RSU net settlement.
  • Remaining Common Stock: Following the transactions, Gerber directly held 12,367 shares of common stock.
  • Remaining RSUs: 3,750 RSUs remain beneficially owned directly after the reported transactions, with an expiration date of September 18, 2027.
  • ESPP Shares: The pre-transaction total of 13,712 shares included 444 shares acquired through the company's Employee Stock Purchase Plan, disclosed as exempt transactions.
  • Vesting Schedule: According to the filing, the RSUs vested or vest as to 1/4 of the total award annually, with the first tranche having vested on September 18, 2024, subject to continued service through each vesting date.

Sutro Biopharma CSO Gerber's RSU Settlement Details

Hans-Peter Gerber, serving as Chief Scientific Officer of Sutro Biopharma, Inc. (NASDAQ:STRO), reported changes in his beneficial ownership of the company's common stock in a Form 4 filed September 22, 2026. The transactions, both dated September 18, 2026, stemmed from the quarterly vesting of restricted stock units originally granted on a schedule vesting 1/4 of the total award annually beginning September 18, 2024.

According to the filing, 3,750 RSUs were converted to common stock at $0 conversion price under transaction code M. Immediately following that acquisition, 1,345 shares were withheld by the issuer at a price of $15.34 per share. The filing states this withholding "does not represent a sale by the reporting person" but rather reflects shares retained by Sutro Biopharma to cover its income tax withholding and remittance obligations in connection with the net settlement of the RSUs.

After both transactions, the filing reports Gerber directly held 12,367 shares of common stock. The filing notes that a prior reported total of 13,712 shares included 444 shares acquired through the issuer's Employee Stock Purchase Plan, described as exempt pursuant to Rules 16a-3(f)(1)(i)(B) and 16b-3(c). In Table II, Gerber's remaining derivative security position stands at 3,750 RSUs held directly, each representing a contingent right to receive one share of common stock upon settlement. The Form 4 was signed by Gregory Chow as attorney-in-fact on September 22, 2026.

What Was Disclosed

The filing discloses RSU vesting and tax-related share withholding transactions by Sutro Biopharma's Chief Scientific Officer on September 18, 2026, resulting in a directly held position of 12,367 shares of common stock and 3,750 remaining RSUs.